Friday Coffee Meetup: Scaling infrastructure for the next generation of cancer care

​Who should attend:

• ​Anyone interested in the latest advancements in cancer treatment and the future of cancer care

• ​Anyone passionate about overcoming challenges in pharmaceutical development

• ​Professionals in the healthcare or pharmaceutical industry

• ​Anyone keen on innovation and entrepreneurship, especially those who love to take solutions from one space and apply them to another

​What's it about:

​Recently, radiopharmaceutical development has re-accelerated with the notable approvals of Lutathera and Pluvicto; both have been effective for neuroendocrine and prostate cancers, respectively, while limiting radiation to healthy tissue within the body.

​However, one major issue surrounding all types of radiopharmaceuticals is the difficulty of navigating the supply chain and supporting expensive development for each drug.

​DropletPharma aims to support pharmaceutical companies of all sizes in scaling development for their radiopharmaceutical pipelines, establishing quick and robust supply for clinical trials, and enabling vast distribution around the world through its development of a new unified platform.

​As new cancer diagnoses each year are projected to increase to 2.2M patients by 2050 in the United States alone, radiopharmaceuticals and DropletPharma aim to play a major role as a scalable and last line of defense against cancer, as well as transitioning this new class of drugs into being the first line of defense.

​Who will you learn from

​Clincy Cheung is the CEO of DropletPharma and oversees the business strategy in close collaboration with his co-founders and bringing a broad range of experience from outside the pharmaceutical sector. He earned his Ph.D. in Materials Science and Engineering from UCLA.